Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study

Purpose Group B streptococcus (GBS) remains a leading cause of invasive disease, mainly sepsis and meningitis, in infants < 3 months of age and of mortality among neonates. This study, a major component of the European DEVANI project (Design of a Vaccine Against Neonatal Infections) describes clinical and important microbiological characteristics of neonatal GBS diseases. It quantifies the rate of antenatal screening and intrapartum antibiotic prophylaxis among cases and identifies risk factors associated with an adverse outcome. Methods Clinical and microbiological data from 153 invasive neonatal cases (82 early-onset [EOD], 71 late-onset disease [LOD] cases) were collected in eight European countries from mid-2008 to end-2010. Results Respiratory distress was the most frequent clinical sign at onset of EOD, while meningitis is found in > 30% of LOD. The study revealed that 59% of mothers of EOD cases had not received antenatal screening, whilst GBS was detected in 48.5% of screened cases. Meningitis was associated with an adverse outcome in LOD cases, while prematurity and the presence of cardiocirculatory symptoms were associated with an adverse outcome in EOD cases. Capsular-polysaccharide type III was the most frequent in both EOD and LOD cases with regional differences in the clonal complex distribution. Conclusions Standardizing recommendations related to neonatal GBS disease and increasing compliance might improve clinical care and the prevention of GBS EOD. But even full adherence to antenatal screening would miss a relevant number of EOD cases, thus, the most promising prophylactic approach against GBS EOD and LOD would be a vaccine for maternal immunization..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:51

Enthalten in:

Infection - 51(2022), 4 vom: 22. Dez., Seite 981-991

Sprache:

Englisch

Beteiligte Personen:

Lohrmann, Florens [VerfasserIn]
Hufnagel, Markus [VerfasserIn]
Kunze, Mirjam [VerfasserIn]
Afshar, Baharak [VerfasserIn]
Creti, Roberta [VerfasserIn]
Detcheva, Antoaneta [VerfasserIn]
Kozakova, Jana [VerfasserIn]
Rodriguez-Granger, Javier [VerfasserIn]
Sørensen, Uffe B. Skov [VerfasserIn]
Margarit, Immaculada [VerfasserIn]
Maione, Domenico [VerfasserIn]
Rinaudo, Daniela [VerfasserIn]
Orefici, Graziella [VerfasserIn]
Telford, John [VerfasserIn]
de la Rosa Fraile, Manuel [VerfasserIn]
Kilian, Mogens [VerfasserIn]
Efstratiou, Androulla [VerfasserIn]
Berner, Reinhard [VerfasserIn]
Melin, Pierrette [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Early-onset disease
Group B streptococcal vaccine
Group B streptococcus
Late-onset disease
Neonatal infection

Anmerkungen:

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s15010-022-01965-x

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2144517959

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?